Pneumonia Testing Market

Pneumonia Testing Market (Test Type: Blood Tests, Imaging Tests, Sputum Tests, Urine Tests, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Pneumonia Testing Market Outlook 2031

  • The industry was valued at US$ 662.6 Mn in 2022
  • It is projected to grow at a CAGR of 3.8% from 2023 to 2031 and reach more than US$ 843.8 Mn by the end of 2031

Analysts’ Viewpoint

Increase in prevalence of pneumonia, advancements in testing technologies, and growth in awareness about the importance of early diagnosis and treatment are some of the key pneumonia testing market drivers. Demand for pneumonia testing is rising owing to the growth in incidence of respiratory infections, particularly in elderly and immunocompromised populations. This is likely to augment pneumonia testing market dynamics in the near future.

Leading players are focusing on developing new, more accurate, and efficient testing technologies for pneumonia, such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP). This is creating lucrative pneumonia testing market opportunities for key players. However, high cost of some of the advanced pneumonia tests in lower-income countries is projected to hamper market statistics during the forecast period.

Pneumonia Testing Market

Market Introduction

Pneumonia testing refers to medical tests used to diagnose pneumonia, a lung infection that causes inflammation in one or both lungs. In some cases, a physician may also order a chest CT scan or a bronchoscopy. The specific tests used for pneumonia diagnosis depend on various factors such as a patient's age, medical history, and symptoms.

Various types of pneumonia testing methods are available in the market. These include chest X-rays, sputum test, blood tests, and rapid antigen test. Increase in adoption of home-based testing and telemedicine is expected to boost pneumonia testing market growth in the near future.

Increase in Prevalence of Pneumonia Augmenting Market Progress

Rise in incidence of pneumonia has resulted in growth in need for accurate and timely diagnosis of the disease. This is driving the demand for pneumonia testing, which helps in identifying the causative agent of the disease and providing appropriate treatment. The elderly population is more susceptible to pneumonia and other respiratory infections.

Pneumonia is one of the leading causes of death worldwide. According to The Centers for Disease Control and Prevention (CDC), pneumonia caused more than 50,000 deaths in the U.S. in 2019. As per the World Health Organization (WHO), pneumonia is a significant global health issue, especially for children under five years of age. In 2019, it was responsible for 14.0% of all deaths in children under five and 22.0% of all deaths in children aged one to five years, resulting in 740,180 deaths worldwide.

Technological Advancements in Pneumonia Testing Methods

Development of new and more sensitive and specific testing methods is augmenting the global pneumonia testing business. The need for rapid and accurate test results has become increasingly important owing the rise in outbreak of pandemics. Rapid diagnostic tests, such as rapid antigen tests, can provide results in just a few minutes, allowing healthcare providers to quickly diagnose and treat patients with pneumonia.

Molecular diagnostic techniques, such as PCR, provide highly accurate results. These techniques are particularly important in detecting antibiotic-resistant strains of pneumonia. Pneumonia is a major global health concern, particularly in developing countries where access to healthcare is limited. Therefore, development of new testing methods is likely to help address this challenge, as early and accurate diagnosis is key to better patient outcomes.

Rise in Government Funding to Develop Efficient and Affordable Testing Methods for Pneumonia

Government agencies are allocating funds to support research and development of new and innovative diagnostic techniques for pneumonia. This is leading to the development of more accurate and efficient tests for pneumonia. Governments are investing in building and expanding healthcare infrastructure, including setting up of diagnostic centers and hospitals. This increased access to healthcare facilities is ultimately fueling the demand for pneumonia testing.

Governments of various countries are implementing policies that mandate the testing of individuals for pneumonia, particularly in high-risk populations such as the elderly, young children, and individuals with underlying health conditions. Several governments are providing subsidies and incentives to healthcare providers and manufacturers to encourage them to develop more affordable pneumonia testing solutions. This is likely to help make testing more accessible to a larger section of the population.

Increase in Need to Prevent Bacterial Pneumonia

As per the pneumonia testing market research report, the bacterial type segment is anticipated to hold major share of the global market during the forecast period.

Pneumonia is often caused by bacterial infections, such as streptococcus pneumoniae and haemophilus influenzae. The bacterial type of pneumonia can be diagnosed through laboratory tests, such as cultures or antigen detection tests, which can accurately identify the specific type of bacterium causing the infection.

Bacterial pneumonia is a common form of pneumonia. Early and accurate diagnosis is crucial in choosing the appropriate treatment. Tests for bacterial pneumonia have high sensitivity and specificity, making them a reliable option for detecting the presence of bacterial infections.

Regional Outlook of Global Pneumonia Testing Industry

According to the global pneumonia testing market forecast report, North America is projected to dominate the global landscape during the forecast period. The pneumonia testing market size in the region is estimated to increase during the forecast period, owing to the high incidence of pneumonia in countries such as the U.S. and growth in awareness about early-stage stage diagnosis and testing.

North America has a well-established medical infrastructure, with advanced laboratory facilities and highly trained medical professionals. It also has strong regulatory support for medical technology, including pneumonia testing. This helps ensure the quality and accuracy of tests and encourages investment in research and development.

As per the pneumonia testing market analysis report, the market in Asia Pacific is growing at a rapid pace due to several factors such as increase in incidence of pneumonia, rise in elderly population, and presence of various governmental initiatives to raise awareness about pneumonia. Growth in healthcare expenditure and development of new and advanced diagnostic technologies are also boosting pneumonia testing market development in Asia Pacific.

High incidence of pneumonia, advanced healthcare infrastructure, presence of several leading players, and rise in awareness about the importance of early diagnosis and treatment are some of the factors contributing to market growth in Europe.

Analysis of Key Players

Large numbers of players, from large multinational corporations to small, niche companies, operate in the global pneumonia testing market. New entrants and existing players are constantly developing and launching new and innovative products to gain an edge in this highly competitive market.

BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BIOMÉRIEUX, Danaher, Hologic, Inc., Quidel Corporation, QIAGEN, Cepheid, Hologic, Inc., Luminex Corporation, and Bio-Rad Laboratories, Inc. are some the key pneumonia testing market players operating across the globe. These players are engaged in mergers & acquisitions and strategic collaborations to increase their market share.

Key Developments

  • In February 2022, Cue Health Inc. and Cardinal Health extended their distribution agreement for Cue's COVID-19 tests, allowing for both professional and over-the-counter use. Cue selected Cardinal Health as a key distributor due to the latter’s successful track record in bringing diagnostic technologies to market. Cardinal Health reaches nearly 90% of LIS hospitals and over 60,000 pharmacies, making this collaboration an important step in increasing the reach and adoption of Cue's innovative nucleic acid amplification test (NAAT) in both traditional and non-traditional healthcare settings.
  • In November 2018, FILMARRAY Pneumonia Panel, a rapid molecular diagnostic test by BIOMÉRIEUX, received clearance from the U.S. Food and Drug Administration (FDA). The test is designed to detect pathogens that cause pneumonia. It helps healthcare professionals diagnose pneumonia more efficiently and accurately, leading to prompt and appropriate treatment decisions. The test analyzes a sample of respiratory secretions and can identify a broad range of bacteria and viruses that can cause pneumonia, including streptococcus pneumoniae, haemophilus influenzae, and Legionella pneumophila.

The pneumonia testing market report profiles the top players based on various parameters including company overview, financial summary, business strategies, product portfolio, business segments, and recent advancements.

Market Snapshot

Attribute

Detail

Size in 2022

US$ 662.6 Mn

Forecast (Value) in 2031

More than US$ 843.8 Mn

Growth Rate (CAGR) 2023-2031

3.8%

Forecast Period

2023–2031

Historical Data Available for

2017–2022

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Test Type
    • Blood Test
    • Imaging Test
    • Sputum Test
    • Urine Test
    • Others
  • Type
    • Bacterial
      • Streptococcus
      • Legionella
      • Chlamydophila
      • Mycoplasma Pneumoniae
    • Viral
    • Others
  • End-user
    • Hospitals & Clinics
    • Diagnostic Laboratories
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • BD (Becton, Dickinson and Company)
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific
  • BIOMÉRIEUX
  • Danaher
  • Hologic, Inc.
  • Quidel Corporation
  • QIAGEN
  • Cepheid
  • Luminex Corporation
  • Bio-Rad Laboratories, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global pneumonia testing market in 2022?

It was valued at US$ 662.6 Mn in 2022

How big will pneumonia testing industry be in 2031?

It is projected to reach more than US$ 843.8 Mn by 2031

What will be the CAGR of the pneumonia testing business during the forecast period?

The CAGR is anticipated to be 3.8% from 2023 to 2031

What is the share of the leading segment?

The bacterial segment accounted for more than 60.0% share in 2022

Which region is expected to account for major share during the forecast period?

North America is likely to account for the largest share during the forecast period

Who are the prominent pneumonia testing players?

BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BIOMÉRIEUX, Danaher, Hologic, Inc., Quidel Corporation, QIAGEN, Cepheid, Luminex Corporation, and Bio-Rad Laboratories, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pneumonia Testing Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pneumonia Testing Market Analysis and Forecast, 2017 - 2031

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Overview of Pneumonia (Causes, Symptoms and Treatment)

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Brief about the Diagnosis/Testing of Pneumonia

    5.4. COVID 19 Impact on Industry

6. Global Pneumonia Testing Market Analysis and Forecast, By Test Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Test Type, 2017 - 2031

        6.3.1. Blood Test

        6.3.2. Imaging Test

        6.3.3. Sputum Test

        6.3.4. Urine Test

        6.3.5. Others

    6.4. Market Attractiveness By Test Type

7. Global Pneumonia Testing Market Analysis and Forecast, By Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast By Type, 2017 - 2031

        7.3.1. Bacterial

            7.3.1.1. Streptococcus

            7.3.1.2. Legionella

            7.3.1.3. Chlamydophila

            7.3.1.4. Mycoplasma Pneumoniae

        7.3.2. Viral

        7.3.3. Others

    7.4. Market Attractiveness By Type

8. Global Pneumonia Testing Market Analysis and Forecast, By End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By End-user, 2017 - 2031

        8.3.1. Hospitals & Clinics

        8.3.2. Diagnostic Laboratories

        8.3.3. Others

    8.4. Market Attractiveness By End-user

9. Global Pneumonia Testing Market Analysis and Forecast, By Region

    9.1. Key Findings

    9.2. Market Value Forecast By Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness By Country/Region

10. North America Pneumonia Testing Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast By Test Type, 2017 - 2031

        10.2.1. Blood Test

        10.2.2. Imaging Test

        10.2.3. Sputum Test

        10.2.4. Urine Test

        10.2.5. Others

    10.3. Market Value Forecast By Type, 2017 - 2031

        10.3.1. Bacterial

            10.3.1.1. Streptococcus

            10.3.1.2. Legionella

            10.3.1.3. Chlamydophila

            10.3.1.4. Mycoplasma Pneumoniae

        10.3.2. Viral

        10.3.3. Others

    10.4. Market Value Forecast By End-user, 2017 - 2031

        10.4.1. Hospitals & Clinics

        10.4.2. Diagnostic Laboratories

        10.4.3. Others

    10.5. Market Value Forecast By Country, 2017 - 2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Test Type

        10.6.2. By Type

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Pneumonia Testing Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast By Test Type, 2017 - 2031

        11.2.1. Blood Test

        11.2.2. Imaging Test

        11.2.3. Sputum Test

        11.2.4. Urine Test

        11.2.5. Others

    11.3. Market Value Forecast By Type, 2017 - 2031

        11.3.1. Bacterial

            11.3.1.1. Streptococcus

            11.3.1.2. Legionella

            11.3.1.3. Chlamydophila

            11.3.1.4. Mycoplasma Pneumoniae

        11.3.2. Viral

        11.3.3. Others

    11.4. Market Value Forecast By End-user, 2017 - 2031

        11.4.1. Hospitals & Clinics

        11.4.2. Diagnostic Laboratories

        11.4.3. Others

    11.5. Market Value Forecast By Country, 2017 - 2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Test Type

        11.6.2. By Type

        11.6.3. By End-user

        11.6.4. By Country

12. Asia Pacific Pneumonia Testing Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Test Type, 2017 - 2031

        12.2.1. Blood Test

        12.2.2. Imaging Test

        12.2.3. Sputum Test

        12.2.4. Urine Test

        12.2.5. Others

    12.3. Market Value Forecast By Type, 2017 - 2031

        12.3.1. Bacterial

            12.3.1.1. Streptococcus

            12.3.1.2. Legionella

            12.3.1.3. Chlamydophila

            12.3.1.4. Mycoplasma Pneumoniae

        12.3.2. Viral

        12.3.3. Others

    12.4. Market Value Forecast By End-user, 2017 - 2031

        12.4.1. Hospitals & Clinics

        12.4.2. Diagnostic Laboratories

        12.4.3. Others

    12.5. Market Value Forecast By Country, 2017 - 2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Test Type

        12.6.2. By Type

        12.6.3. By End-user

        12.6.4. By Country

13. Latin America Pneumonia Testing Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast By Test Type, 2017 - 2031

        13.2.1. Blood Test

        13.2.2. Imaging Test

        13.2.3. Sputum Test

        13.2.4. Urine Test

        13.2.5. Others

    13.3. Market Value Forecast By Type, 2017 - 2031

        13.3.1. Bacterial

            13.3.1.1. Streptococcus

            13.3.1.2. Legionella

            13.3.1.3. Chlamydophila

            13.3.1.4. Mycoplasma Pneumoniae

        13.3.2. Viral

        13.3.3. Others

    13.4. Market Value Forecast By End-user, 2017 - 2031

        13.4.1. Hospitals & Clinics

        13.4.2. Diagnostic Laboratories

        13.4.3. Others

    13.5. Market Value Forecast By Country, 2017 - 2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Test Type

        13.6.2. By Type

        13.6.3. By End-user

        13.6.4. By Country

14. Middle East & Africa Pneumonia Testing Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast By Test Type, 2017 - 2031

        14.2.1. Blood Test

        14.2.2. Imaging Test

        14.2.3. Sputum Test

        14.2.4. Urine Test

        14.2.5. Others

    14.3. Market Value Forecast By Type, 2017 - 2031

        14.3.1. Bacterial

            14.3.1.1. Streptococcus

            14.3.1.2. Legionella

            14.3.1.3. Chlamydophila

            14.3.1.4. Mycoplasma Pneumoniae

        14.3.2. Viral

        14.3.3. Others

    14.4. Market Value Forecast By End-user, 2017 - 2031

        14.4.1. Hospitals & Clinics

        14.4.2. Diagnostic Laboratories

        14.4.3. Others

    14.5. Market Value Forecast By Country, 2017 - 2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Test Type

        14.6.2. By Type

        14.6.3. By End-user

        14.6.4. By Country

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis By Company (2022)

    15.3. Company Profiles

        15.3.1. BD (Becton, Dickinson and Company)

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. F. Hoffmann-La Roche Ltd.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Abbott

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Siemens Healthcare GmbH

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Thermo Fisher Scientific Inc.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. BIOMÉRIEUX

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Danaher

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Hologic, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Quidel Corporation

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. QIAGEN

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

        15.3.11. Cepheid

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Product Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

        15.3.12. Hologic, Inc.

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Product Portfolio

            15.3.12.3. Financial Overview

            15.3.12.4. SWOT Analysis

            15.3.12.5. Strategic Overview

        15.3.13. Luminex Corporation

            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.13.2. Product Portfolio

            15.3.13.3. Financial Overview

            15.3.13.4. SWOT Analysis

            15.3.13.5. Strategic Overview

        15.3.14. Bio-Rad Laboratories, Inc.

            15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.14.2. Product Portfolio

            15.3.14.3. Financial Overview

            15.3.14.4. SWOT Analysis

            15.3.14.5. Strategic Overview

List of Tables

Table 01: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 02: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 03: Global Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 04: Global Pneumonia Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 06: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 07: North America Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 08: North America Pneumonia Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 10: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 11: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 12: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 14: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 15: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 16: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 18: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 19: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 20: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 22: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, By End-user, 2017–2031

Table 24: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 03: Global Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 04: Global Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 05: Global Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 06: Global Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 07: Global Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 08: Global Pneumonia Testing Market Value Share Analysis, by Region, 2022 and 2031

Figure 09: Global Pneumonia Testing Market Attractiveness Analysis, by Region, 2023–2031

Figure 10: North America Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 12: North America Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 13: North America Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 14: North America Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 15: North America Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 16: North America Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 17: North America Pneumonia Testing Market Value Share Analysis, by Country, 2022 and 2031

Figure 18: North America Pneumonia Testing Market Attractiveness Analysis, by Country, 2023–2031

Figure 19: Europe Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 20: Europe Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 21: Europe Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 22: Europe Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 23: Europe Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 24: Europe Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 25: Europe Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 26: Europe Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 27: Europe Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 28: Asia Pacific Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 29: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 30: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 31: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 32: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 33: Asia Pacific Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 34: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 35: Asia Pacific Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 36: Asia Pacific Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 37: Latin America Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 38: Latin America Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 39: Latin America Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 40: Latin America Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 41: Latin America Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 42: Latin America Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 43: Latin America Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 44: Latin America Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 45: Latin America Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 46: Middle East & Africa Pneumonia Testing Market Value (US$ Mn) Forecast, 2017–2031

Figure 47: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Test Type, 2022 and 2031

Figure 48: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Test Type, 2023–2031

Figure 49: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Type, 2022 and 2031

Figure 50: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Type, 2023–2031

Figure 51: Middle East & Africa Pneumonia Testing Market Value Share Analysis, By End-user, 2022 and 2031

Figure 52: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, By End-user, 2023–2031

Figure 53: Middle East & Africa Pneumonia Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 54: Middle East & Africa Pneumonia Testing Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 55: Global Pneumonia Testing Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved